Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    DESSOLVE III
Previous Study | Return to List | Next Study

Study Comparing the MiStent SES Versus the XIENCE EES Stent (DESSOLVE III)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02385279
Recruitment Status : Active, not recruiting
First Posted : March 11, 2015
Last Update Posted : December 19, 2020
Sponsor:
Collaborators:
Micell Technologies
Stentys
Information provided by (Responsible Party):
ECRI bv

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary objective of this study is to compare the performance of MISTENT to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease. The patients will be followed through 3 years for major clinical events.

Condition or disease Intervention/treatment Phase
Coronary Stenosis Device: MiStent Device: XIENCE EES Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1404 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries
Actual Study Start Date : March 20, 2015
Actual Primary Completion Date : January 31, 2017
Estimated Study Completion Date : January 2021
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: MiStent®
Percutaneous Coronary Intervention with the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent. It is a balloon expandable sirolimus eluting stent with an absorbable polymer coating.
 Device: MiStent
Percutaneous Coronary Intervention
Active Comparator: XIENCE EES
Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
 Device: XIENCE EES
Percutaneous Coronary Intervention


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Non inferiority comparison of a device oriented composite endpoint (DOCE) or Target Lesion Failure (TLF) of the MISTENT group to the XIENCE group [ Time Frame: 12 months postprocedure ]
    TLF is a composite of clinical endpoint of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel and clinically-indicated target lesion revascularization.


Secondary Outcome Measures :
  1. POCE defined as all-cause death, any Myocardial Infarction (MI), or any revascularization [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
  2. MACE defined as all-cause death, any MI, or any Target Vessel Revascularization (TVR) [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
  3. Target Vessel Failure (TVF) defined as cardiac death, TV MI, or clinically indicated TVR [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
  4. DOCE/TLF defined as cardiac death, TV MI or clinically indicated Target Lesion Revascularization (TLR) [ Time Frame: 30 days, 6 months, 2 years, 3 years ]
  5. Mortality [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
  6. Myocardial infarction [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
  7. Revascularization [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]
  8. Stent thrombosis rates according to ARC classification [ Time Frame: 30 days, 6 months, 1 year, 2 years and 3 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

All comers" patients:

  • Male or female patients 18 years or older;
  • Presence of one or more coronary artery stenoses of 50% or more in a native coronary artery or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation.
  • The vessel should have a reference vessel diameter ranging from 2.5 mm to 3.75 mm (no limitation on the number of treated lesions, vessels, or lesion length); All lesions of the patient must comply with the angiographic inclusion criteria.
  • The patient is judged to be capable of providing voluntary informed consent and has been fully informed of the nature of the study, is willing to comply with all study requirements and will provide written informed consent as approved by the Ethics Committee of the respective clinical site.

Exclusion Criteria:

  • Known pregnancy or breastfeeding at time of randomization;
  • Known contraindication or hypersensitivity to sirolimus, everolimus, cobalt-chromium, or to medications such as aspirin, heparin, bivalirudin, and all of the following four medications: clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor;
  • Concurrent medical condition with a life expectancy of less than 12 months.
  • The patient is unwilling/ not able to return for outpatient clinic at 1 month and 12 months follow-up.
  • Currently participating in another trial and not yet at its primary endpoint.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02385279


Locations
Show Show 20 study locations
Sponsors and Collaborators
ECRI bv
Micell Technologies
Stentys
Investigators
Layout table for investigator information
Principal Investigator: P. W. Serruys, Prof. MD. International Center for Circulatory Health, NHLI, Imperial College, London, United Kingdom
Principal Investigator: W Wijns, Prof. MD. Hartcenter, OLV Aalst, Belgium
Principal Investigator: R. de Winter, Prof. MD. Academisch Medisch Centrum, Amsterdam, The Netherlands
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: ECRI bv
ClinicalTrials.gov Identifier: NCT02385279    
Other Study ID Numbers: ECRI-005
First Posted: March 11, 2015    Key Record Dates
Last Update Posted: December 19, 2020
Last Verified: December 2020
Keywords provided by ECRI bv:
CAD
ACS
All comers
PCI
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Stenosis
Coronary Disease
Myocardial Ischemia
 Heart Diseases
Cardiovascular Diseases
Vascular Diseases